HIV-1
Jul 28, 2026
Ultomiris Phase III Trial Update Highlights Progress in Post-Transplant TMA; argenx Acquires Forte Biosciences; Otsuka’s SIMTRIYO Receives FDA Nod as a First-in-Class ADHD Treatment; Outlook Therapeutics Secures FDA Approval for LYTENAVA to Treat Wet AMD; Merck Reveals Future Access Strategy for Once-Monthly Oral HIV Prevention Therapy Alimatravir
Phase III Ultomiris Trial Reports Progress in Adults and Adolescents with HSCT-Related TMA Topline findings from the Phase III ALXN1210-TMA-313 trial indicated that Ultomiris (ravulizumab) did not meet the primary endpoint of event-free survival over 26 weeks versus placebo in adults and adolescents (12 years an...
Read More...
Jun 24, 2025
Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria
Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma Incyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the f...
Read More...
Oct 29, 2021
Changing Dynamics of HIV-1 Treatment Market
The HIV-1 treatment market for naïve and experienced patients is evolving consistently. Some of the major changes include the preference of single-tablet regimens (STRs) over multiple tablet regimens (MTRs), tenofovir alafenamide (TAF)-based therapies over tenofovir disoproxil fumarate (TDF)-based therapies, integr...
Read More...
Feb 20, 2015
Gene Therapy to “Assassinate” HIV virus
Transforming Cells into Molecular Assassins The conventional approach to vaccination involves training the immune system to fight an infection. But the Researchers at Scripps Research Institute in California have derived a new technique that involves altering the DNA in order to give cells anti-HIV capabilities. A...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
